Amphastar Pharmaceuticals Croissance future
Future contrôle des critères 0/6
Les bénéfices de Amphastar Pharmaceuticals devraient diminuer de 0.7% par an tandis que son chiffre d'affaires annuel devrait croître de 3.8% par an. Le BPA devrait croître de diminuer de 2.5% par an. Le rendement des capitaux propres devrait être 15% dans 3 ans.
Informations clés
-0.7%
Taux de croissance des bénéfices
-2.51%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 14.4% |
| Taux de croissance des recettes | 3.8% |
| Rendement futur des capitaux propres | 14.97% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 14 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 10
AMPH: Buybacks And New Approvals Will Support Future Upside Potential
Narrative Update on Amphastar Pharmaceuticals The latest analyst work has trimmed Amphastar Pharmaceuticals' implied fair value to about $26.86 from $28.00, as analysts factor in recent price target cuts from multiple firms and a slightly higher discount rate tied to softer revenue guidance despite recent product approvals. Analyst Commentary Recent research on Amphastar Pharmaceuticals has turned more cautious, with multiple firms trimming price targets and one downgrade reflecting concerns around revenue guidance and execution, even as new products win approvals.Seeking Alpha • Apr 30
Amphastar: A Cheap Multiple Doing Exactly What It's Supposed To Do
Summary Amphastar Pharmaceuticals trades at a deep discount—6.7x trailing earnings—reflecting structural growth and margin challenges. Branded product growth (BAQSIMI, Primatene MIST) has not offset accelerating legacy generic erosion, resulting in flat or declining revenues. 2026 guidance has already been cut; gross margins are guided lower, and consensus estimates likely remain too high heading into Q1 earnings. I maintain a HOLD rating, leaning bearish, pending a clean AMP-007 launch or transformative business development. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 24
AMPH: Revised Outlook Suggests Future Upside As New Therapies Scale
Narrative Update on Amphastar Pharmaceuticals The analyst price target for Amphastar Pharmaceuticals has shifted from $38 to $30 as analysts factor in revised revenue guidance, lower projected profit margins, and a higher assumed future P/E multiple. They also note the potential importance of AMP-007 for achieving mid to high single digit revenue growth targets.Mise à jour du récit • Apr 10
AMPH: Share Repurchases And New Launches Will Support Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate by $1 to about $28, reflecting lower Street price targets and cautious views on revised revenue guidance despite recent product approvals. Analyst Commentary Recent Street research on Amphastar shares points to a more cautious tone after the latest revenue guidance update and lower price targets, even as new products move through the approval pipeline.Mise à jour du récit • Mar 26
AMPH: Softer Guidance And Execution Risk Will Shape Future Upside Potential
Analysts have trimmed Amphastar Pharmaceuticals' fair value estimate from $32.00 to $29.00. This reflects updated views on softer revenue guidance, lower projected profit margins, a slightly higher discount rate, and a higher assumed future P/E multiple in light of recent price target cuts to $30.00 from several firms.
Mise à jour du récit • Mar 12
AMPH: Softer Guidance And Pipeline Risk Will Still Support Future Upside
Analysts have modestly reduced their price targets on Amphastar Pharmaceuticals to $30, reflecting concerns about softer revenue guidance and pipeline execution risk. At the same time, recent product approvals and revised earnings assumptions support a slightly higher modeled fair value and P/E multiple in our framework.Mise à jour du récit • Feb 26
AMPH: Pipeline Execution Risk Will Cap Upside Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, citing cautious views on pipeline execution risk, even as they still see the shares as undervalued relative to peers and historical valuation. Analyst Commentary Recent research updates reflect a more cautious tone, with bearish analysts trimming price expectations even while acknowledging that Amphastar still trades at what they view as a discount to peers and its own history.Mise à jour du récit • Feb 09
AMPH: Pipeline Execution Risk Will Drive Cautious View Despite Lowered US$30 Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31, reflecting a cautious view on pipeline execution risk, even as they see the shares as undervalued relative to historical and peer valuations. Analyst Commentary Bearish analysts have trimmed their price target on Amphastar Pharmaceuticals to US$30 from US$31 as coverage transitions, signaling a cautious stance on how the company can deliver on its current pipeline while justifying its valuation.Mise à jour du récit • Jan 25
AMPH: Buybacks And Pipeline Risk Will Shape Cautious Yet Balanced Outlook
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31, reflecting updated views on revenue growth, margin assumptions, and future P/E expectations, along with ongoing caution around pipeline execution risk. Analyst Commentary Bearish analysts have taken a slightly more cautious stance, trimming the price target to US$30 from US$31 as coverage transitions to a new lead.Mise à jour du récit • Jan 11
AMPH: Pipeline Execution Risk Will Shape Cautious View Despite Buybacks
Analysts have trimmed their price target on Amphastar Pharmaceuticals to $30 from $31. The revised target reflects fresh coverage that balances a view of the shares as undervalued on comps and historical valuation with caution around pipeline execution risk.Mise à jour du récit • Dec 13
AMPH: Q3 Drug Trends And Buybacks Will Shape Balanced Near-Term Outlook
Analysts have modestly lowered their price target on Amphastar Pharmaceuticals to $31 from $32, citing recent Q3 pricing and volume trends for key drugs and a largely unchanged outlook for near term earnings and 2026 estimates. Analyst Commentary Bearish analysts have highlighted that the modest reduction in the price target reflects growing caution around the durability of Amphastar's recent performance, particularly in light of more muted pricing and volume trends observed in the third quarter.Article d’analyse • Jul 01
Earnings Working Against Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Share Price
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 7.6x might make it look like a...Article d’analyse • Apr 04
We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 19
Amphastar Pharmaceuticals: A Gradual Strategy
Summary Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside. My strategy includes a 0.75x position weight and a gradual approach combining the stock with a Covered Call. Read the full article on Seeking AlphaArticle d’analyse • Jan 03
These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Dec 16
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.9x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...Article d’analyse • Nov 28
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Oct 25
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Summary Amphastar's Q2 2024 revenue grew 25% year-over-year to $182.4 million, primarily driven by BAQSIMI and Primatene MIST sales. Primatene MIST faces future challenges as its key patent expires in 2026, limiting long-term revenue potential. BAQSIMI contributed $38.5 million in Q2 2024 sales, affirming its strategic acquisition from Eli Lilly. Amphastar’s heavy reliance on a few high-margin products, like glucagon and epinephrine, may limit future growth due to rising competition. I recommend holding Amphastar as current valuations seem fair, but growth prospects are uncertain due to product competition and patent expirations. Read the full article on Seeking AlphaArticle d’analyse • Sep 15
Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Amphastar Pharmaceuticals, Inc.'s ( NASDAQ:AMPH ) price-to-earnings (or "P/E") ratio of 14.1x might make it look like a...Seeking Alpha • Sep 12
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Summary Amphastar Pharmaceuticals has seen significant growth since its 2014 IPO, with its stock price increasing over 500% to $45 per share. The acquisition of Baqsimi from Eli Lilly is a key revenue driver, but its long-term profitability remains uncertain due to milestone payments. Amphastar's revenue growth from epinephrine and Primatene Mist may not be sustainable, and the company faces intense competition in these markets. The pipeline's future is unclear, with several FDA rejections and no standout products, leading to a "Hold" rating on Amphastar stock. Read the full article on Seeking Alpha
Nouveau récit • Sep 10
Decisive Acquisitions And Production Innovations Propel Pharma Growth And Market Dominance
Emphasis on proprietary products and strategic acquisitions to enhance market presence and contribute significantly to revenue growth.Article d’analyse • Aug 27
Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Article d’analyse • Jul 05
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 01
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Summary AMPH has materially benefited from a variety of temporary factors across their key product lines that have largely gone unnoticed by investors, sending shares up ~100% over the last 3yrs. Amphastar’s glucagon business has benefited from shortages at Fresenius, which were recently rectified. Three new competitors are about to launch glucagon, turning this duopoly into a potential 5-player market. Epinephrine revenues should meaningfully disappoint as shortage benefits alleviate, a newly approved competitor ramps, and two potential competitors gain approval. The sole Orange Book patent on Primatene MIST, a key high margin product, expires in January 2026, which opens the door to material competition. Primatene is one of the few DTC products in its aisle without a generic. A handful of smaller “Other” products have been buoyed by a tornado which took out competitor Pfizer’s product warehousing. The magnitude of the benefit is larger than investors believe, and Pfizer is quickly returning to market. Read the full article on Seeking AlphaArticle d’analyse • May 30
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 17x, you may...Seeking Alpha • May 30
Amphastar Pharmaceuticals: Buy When Fear Is Overblown
Summary Seeking Alpha's screener identified Amphastar Pharmaceuticals as a potential investment candidate based on its solid financials, positive growth in revenue and earnings. Despite its strong financials and potential for earnings growth, the company's stock fell 31% in 5 months. The article aims to uncover the reasons behind the price decline to determine if the price decline is a temporary setback that offers an opportunity for value investors. Read the full article on Seeking AlphaSeeking Alpha • May 15
Reassessing Amphastar Pharmaceuticals
Summary Amphastar Pharmaceuticals, Inc. stock is down approximately 30% this year, and the company reported mixed Q1 results last week. Despite the poor performance of the stock so far in 2024, there are some positives on the company and its stock. An updated analysis around Amphastar Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Mar 27
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Mar 04
Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Summary Amphastar Pharmaceuticals specializes in developing, manufacturing, and distributing pharmaceutical products, with a focus on strategic acquisitions. The company's portfolio includes high-margin products such as Primatene MIST and Glucagon Injection for severe hypoglycemia. Amphastar's pipeline includes promising upcoming products such as Rextovy, and its recent acquisition of Baqsimi enhances its position in diabetes management. AMPH's financials indicate manageable debt levels and the potential for continued revenue growth and profitability, reinforcing its investment appeal. My valuation analysis suggests AMPH is undervalued compared to peers, with strong business fundamentals supporting a "Strong Buy" rating. Read the full article on Seeking AlphaArticle d’analyse • Jan 04
Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Article d’analyse • Dec 20
Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
With a price-to-earnings (or "P/E") ratio of 21.4x Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) may be sending...Article d’analyse • Dec 03
Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 809 | 79 | 136 | 176 | 5 |
| 12/31/2027 | 788 | 84 | 138 | 172 | 6 |
| 12/31/2026 | 747 | 64 | 129 | 196 | 6 |
| 3/31/2026 | 721 | 79 | 133 | 169 | N/A |
| 12/31/2025 | 720 | 98 | 119 | 156 | N/A |
| 9/30/2025 | 723 | 112 | 111 | 152 | N/A |
| 6/30/2025 | 723 | 135 | 110 | 160 | N/A |
| 3/31/2025 | 731 | 142 | 150 | 193 | N/A |
| 12/31/2024 | 732 | 160 | 172 | 213 | N/A |
| 9/30/2024 | 724 | 158 | 170 | 208 | N/A |
| 6/30/2024 | 713 | 167 | 178 | 213 | N/A |
| 3/31/2024 | 676 | 155 | 161 | 198 | N/A |
| 12/31/2023 | 644 | 138 | 145 | 184 | N/A |
| 9/30/2023 | 601 | 135 | 140 | 175 | N/A |
| 6/30/2023 | 541 | 102 | 100 | 131 | N/A |
| 3/31/2023 | 519 | 93 | 51 | 79 | N/A |
| 12/31/2022 | 499 | 91 | 65 | 89 | N/A |
| 9/30/2022 | 485 | 77 | 90 | 114 | N/A |
| 6/30/2022 | 477 | 91 | 70 | 97 | N/A |
| 3/31/2022 | 455 | 81 | 100 | 126 | N/A |
| 12/31/2021 | 438 | 62 | 71 | 98 | N/A |
| 9/30/2021 | 413 | 36 | 45 | 74 | N/A |
| 6/30/2021 | 384 | 10 | 52 | 81 | N/A |
| 3/31/2021 | 368 | 2 | 45 | 79 | N/A |
| 12/31/2020 | 350 | 1 | 23 | 57 | N/A |
| 9/30/2020 | 337 | 7 | 13 | 46 | N/A |
| 6/30/2020 | 334 | 4 | -11 | 25 | N/A |
| 3/31/2020 | 327 | 52 | 12 | 47 | N/A |
| 12/31/2019 | 322 | 49 | N/A | 42 | N/A |
| 9/30/2019 | 329 | 52 | N/A | 46 | N/A |
| 6/30/2019 | 324 | 53 | N/A | 73 | N/A |
| 3/31/2019 | 316 | 2 | N/A | 26 | N/A |
| 12/31/2018 | 295 | -6 | N/A | 38 | N/A |
| 9/30/2018 | 265 | -7 | N/A | 38 | N/A |
| 6/30/2018 | 248 | -9 | N/A | 25 | N/A |
| 3/31/2018 | 242 | -4 | N/A | 25 | N/A |
| 12/31/2017 | 240 | 4 | N/A | 39 | N/A |
| 9/30/2017 | 243 | 0 | N/A | 43 | N/A |
| 6/30/2017 | 250 | 4 | N/A | 42 | N/A |
| 3/31/2017 | 252 | 9 | N/A | 47 | N/A |
| 12/31/2016 | 255 | 10 | N/A | 39 | N/A |
| 9/30/2016 | 269 | 21 | N/A | 28 | N/A |
| 6/30/2016 | 268 | 14 | N/A | 30 | N/A |
| 3/31/2016 | 254 | 0 | N/A | 23 | N/A |
| 12/31/2015 | 252 | -3 | N/A | 11 | N/A |
| 9/30/2015 | 230 | -13 | N/A | 20 | N/A |
| 6/30/2015 | 226 | -15 | N/A | 30 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Les bénéfices de AMPH devraient diminuer au cours des 3 prochaines années ( -0.7% par an).
Bénéfices vs marché: Les bénéfices de AMPH devraient diminuer au cours des 3 prochaines années ( -0.7% par an).
Croissance élevée des bénéfices: Les bénéfices de AMPH devraient baisser au cours des trois prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de AMPH ( 3.8% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de AMPH ( 3.8% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de AMPH devrait être faible dans 3 ans ( 15 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/14 01:25 |
| Cours de l'action en fin de journée | 2026/05/14 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Amphastar Pharmaceuticals, Inc. est couverte par 14 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Jason Matthew Gerberry | BofA Global Research |